JP7721635B2 - 糖鎖及び糖鎖を含む医薬品の製造方法 - Google Patents

糖鎖及び糖鎖を含む医薬品の製造方法

Info

Publication number
JP7721635B2
JP7721635B2 JP2023505652A JP2023505652A JP7721635B2 JP 7721635 B2 JP7721635 B2 JP 7721635B2 JP 2023505652 A JP2023505652 A JP 2023505652A JP 2023505652 A JP2023505652 A JP 2023505652A JP 7721635 B2 JP7721635 B2 JP 7721635B2
Authority
JP
Japan
Prior art keywords
compound
formula
compound represented
group
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023505652A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022191313A1 (https=
JPWO2022191313A5 (https=
Inventor
剛 上田
恵介 鈴木
龍生 伊東
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of JPWO2022191313A1 publication Critical patent/JPWO2022191313A1/ja
Publication of JPWO2022191313A5 publication Critical patent/JPWO2022191313A5/ja
Priority to JP2025126121A priority Critical patent/JP2025160360A/ja
Application granted granted Critical
Publication of JP7721635B2 publication Critical patent/JP7721635B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/044—Pyrrole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023505652A 2021-03-12 2022-03-11 糖鎖及び糖鎖を含む医薬品の製造方法 Active JP7721635B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025126121A JP2025160360A (ja) 2021-03-12 2025-07-29 糖鎖及び糖鎖を含む医薬品の製造方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021040164 2021-03-12
JP2021040164 2021-03-12
PCT/JP2022/010851 WO2022191313A1 (ja) 2021-03-12 2022-03-11 糖鎖及び糖鎖を含む医薬品の製造方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025126121A Division JP2025160360A (ja) 2021-03-12 2025-07-29 糖鎖及び糖鎖を含む医薬品の製造方法

Publications (3)

Publication Number Publication Date
JPWO2022191313A1 JPWO2022191313A1 (https=) 2022-09-15
JPWO2022191313A5 JPWO2022191313A5 (https=) 2025-03-04
JP7721635B2 true JP7721635B2 (ja) 2025-08-12

Family

ID=83228168

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023505652A Active JP7721635B2 (ja) 2021-03-12 2022-03-11 糖鎖及び糖鎖を含む医薬品の製造方法
JP2025126121A Pending JP2025160360A (ja) 2021-03-12 2025-07-29 糖鎖及び糖鎖を含む医薬品の製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025126121A Pending JP2025160360A (ja) 2021-03-12 2025-07-29 糖鎖及び糖鎖を含む医薬品の製造方法

Country Status (9)

Country Link
US (1) US20240279364A1 (https=)
EP (1) EP4306546A4 (https=)
JP (2) JP7721635B2 (https=)
KR (1) KR20230157983A (https=)
CN (2) CN121021596A (https=)
BR (1) BR112023017365A2 (https=)
CA (1) CA3212691A1 (https=)
IL (1) IL305816A (https=)
WO (1) WO2022191313A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250064682A (ko) * 2022-09-09 2025-05-09 다이이찌 산쿄 가부시키가이샤 신규 올리고당, 그 올리고당의 제조 중간체, 및 그것들의 제조 방법

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6051702A (ja) * 1983-08-30 1985-03-23 Rikagaku Kenkyusho 複合多糖およびその製造法
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1996002255A1 (en) 1994-07-15 1996-02-01 Taiyo Kagaku Co., Ltd. Medicinal composition containing sialic acid derivative
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU2002311919B8 (en) 2001-05-11 2007-03-22 Ludwig Institute For Cancer Research Ltd Specific binding proteins and uses thereof
WO2004008099A2 (en) 2002-07-15 2004-01-22 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES
JP5356648B2 (ja) 2003-02-20 2013-12-04 シアトル ジェネティックス， インコーポレイテッド 抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
NZ566395A (en) 2005-09-26 2012-03-30 Medarex Inc Human monoclonal antibodies to CD70
JP2009155353A (ja) * 2006-03-30 2009-07-16 Yokohama City Univ 糖鎖化合物の製造方法
BRPI0816094A2 (pt) 2007-08-30 2015-03-03 Daiichi Sankyo Co Ltd Anticorpo, polipeptídeo, hibridoma, composição farmacêutica, método para inibir o desenvolvimento de tumor em um mamífero, polinucleotídeo, célula hospedeira, e, método para produzir um anticorpo.
US8809496B2 (en) 2009-09-03 2014-08-19 The Noguchi Institute Production method of 11-sugar sialylglycopeptide
US10851174B2 (en) * 2011-03-03 2020-12-01 University Of Maryland, Baltimore Core fucosylated glycopeptides and glycoproteins: chemoenzymatic synthesis and uses thereof
WO2012135049A1 (en) * 2011-03-25 2012-10-04 University Of Georgia Research Foundation, Inc. Compounds and methods for chemical and chemo-enzymatic synthesis of complex glycans
ES2773710T3 (es) 2012-10-11 2020-07-14 Daiichi Sankyo Co Ltd Enlazadores para conjugados de anticuerpo - fármaco
TW201442721A (zh) * 2013-01-23 2014-11-16 Daiichi Sankyo Co Ltd 糖鏈修飾心房利尿鈉肽
TW201534613A (zh) 2013-06-28 2015-09-16 Daiichi Sankyo Co Ltd 寡糖胜肽之純化方法
WO2015080603A1 (en) * 2013-11-28 2015-06-04 Antony John Fairbanks Glycoproteins
AU2014371934B2 (en) 2013-12-25 2020-01-23 Daiichi Sankyo Company, Limited Anti-TROP2 antibody-drug conjugate
US11559581B2 (en) 2015-01-09 2023-01-24 Oxford University Innovation Limited Antibody conjugates and methods of making the antibody conjugates
WO2017110984A1 (ja) 2015-12-25 2017-06-29 第一三共株式会社 限外ろ過膜を用いたオリゴ糖ペプチドの精製法
WO2018003983A1 (ja) 2016-07-01 2018-01-04 第一三共株式会社 ｈＡＮＰ－Ｆｃ含有分子コンジュゲート
JP6342968B2 (ja) * 2016-07-25 2018-06-13 株式会社伏見製薬所 糖誘導体の製造方法及び新規糖誘導体
TW202532104A (zh) 2017-05-15 2025-08-16 日商第一三共股份有限公司 抗體－藥物結合物及其用途
NZ762505A (en) 2017-09-29 2026-03-27 Daiichi Sankyo Co Ltd Antibody-pyrrolobenzodiazepine derivative conjugate
EP3848054B1 (en) 2018-09-06 2025-01-29 Daiichi Sankyo Company, Limited Antibody-drug conjugates of cyclic dinucleotide derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Organic & Biomolecular Chemistry，2018年，16(25)，4720-4727，DOI: 10.1039/c8ob01046c

Also Published As

Publication number Publication date
WO2022191313A1 (ja) 2022-09-15
CA3212691A1 (en) 2022-09-15
CN121021596A (zh) 2025-11-28
JP2025160360A (ja) 2025-10-22
CN116917341B (zh) 2025-09-23
JPWO2022191313A1 (https=) 2022-09-15
BR112023017365A2 (pt) 2023-10-03
US20240279364A1 (en) 2024-08-22
KR20230157983A (ko) 2023-11-17
IL305816A (en) 2023-11-01
CN116917341A (zh) 2023-10-20
EP4306546A4 (en) 2025-06-18
EP4306546A1 (en) 2024-01-17

Similar Documents

Publication Publication Date Title
US20110245488A1 (en) Process for the synthesis of l-fucosyl di- or oligo-saccharides and novel 2,3,4 tribenzyl-fucosyl derivatives intermediates thereof
KR102920761B1 (ko) 시알리다제-내성 당류 및 이의 제조 및 사용 방법
CN103703012A (zh) 乳糖-n-四糖的制造
JPH11510490A (ja) ルイスｙエピトープの複合糖質の合成及びこれらの使用
JP2025160360A (ja) 糖鎖及び糖鎖を含む医薬品の製造方法
EP4585601A1 (en) Novel oligosaccharide, production intermediate for novel oligosaccharide, production method for novel oligosaccharide, and production method for production intermediate for novel oligosaccharide
CN114874345A (zh) 一种幽门螺旋杆菌核心脂多糖寡糖抗原糖链的化学合成方法
US20090155299A1 (en) Antibodies for the Detection of Bacillus Anthracis and Vaccine Against B. Anthracis Infections
Keding et al. Synthesis of non-natural glycosylamino acids containing tumor-associated carbohydrate antigens
WO2001014395A2 (en) Novel glycoconjugates, glycoamino, acids, intermediates thereto, and uses thereof
US20250346622A1 (en) Novel oligosaccharide, manufacturing intermediate for novel oligosaccharide, and method for manufacturing these
HK40106086A (en) Glycan, and method for producing medicine containing glycan
Cho et al. Organic synthesis in pursuit of immunology: Large-scale synthesis of peracetylated GM2 glycosylamino acid for preparation of a multiantigenic prostate cancer vaccine
JP6198207B2 (ja) 新規糖供与体及びそれを用いた糖鎖の合成方法
JP7837312B2 (ja) 新規な脱アルコキシフェニル化反応
CN118302451A (zh) 新型寡糖、该寡糖的制造中间体、以及它们的制造方法
HK40109704A (en) Novel oligosaccharide, manufacturing intermediate for novel oligosaccharide, and method for manufacturing these
HK40108200A (en) Novel dealkoxyphenylation reaction
JP5015505B2 (ja) コア４型構造を有するｏ−結合型糖タンパク質糖鎖関連化合物およびその製造方法
EP1849794A1 (en) Process for producing 1,2-trans-glycoside compound
JP2002525375A (ja) ウロソン酸のｃ−グリコシドの合成方法
CN1334268A (zh) 一种可作药用的阿拉伯－半乳多糖的活性四糖片段的合成
NZ793831A (en) Steroids and protein-conjugates thereof
JP2007022985A (ja) コア６型構造を有するｏ−結合型糖アミノ酸誘導体およびその製造方法
JP2010235593A (ja) 糖１−ボラノホスフェート化合物の立体選択的製造方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250616

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250701

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250730

R150 Certificate of patent or registration of utility model

Ref document number: 7721635

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150